


Claims

1. A compound of the formula,

5



(I)

wherein

10 R¹ is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;


15 R² is hydrogen or methyl;

R³ is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

- 20
2. The compound according to Claim 1, wherein R¹ is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, or (L)-ornityl-(D)-ornitylamino.
 3. The compound according to Claim 1, wherein R² and R³ are hydrogen.
 4. The compound according to Claim 1, wherein R¹ is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, and R² and R³ are hydrogen.

5. The compound according to Claim 1, wherein R¹ is (L)-ornityl-(D)-ornitylamino, and R² and R³ are hydrogen.
6. The compound according to Claim 1, wherein R¹ is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R² and R³ are hydrogen.
- 5 7. The compound according to Claim 1, wherein R¹ is N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R² and R³ are hydrogen.
8. The compound according to Claim 1, wherein R¹ is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, and R² and R³ are hydrogen.
9. The compound according to Claim 1, wherein R¹ is N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R² and R³ are hydrogen.
- 10 10. The compound according to Claim 1 wherein R² is methyl and R³ is hydrogen.
11. The compound according to Claim 1 wherein R² is hydrogen and R³ is hydroxyl.
12. A pharmaceutical composition comprising a mixture of a pharmaceutically acceptable carrier and an effective amount of a compound of the formula



15

wherein


R¹ is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

20

R² is hydrogen or methyl;

R³ is hydrogen or hydroxy;
or a pharmaceutically acceptable salt thereof.

13. A method for the prophylactic and/or therapeutic treatment of mycoses which comprises
5 administering to a human being or an animal an effective amount of the compound of the formula



wherein

10 R¹ is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornityl-amino;

R² is hydrogen or methyl;

R³ is hydrogen or hydroxy;

15 or a pharmaceutically acceptable salt thereof.
